Forte Research Systems, Inc. is pleased to introduce the newest member of the Allegro® product line, Allegro CTMS@Network™, which addresses key challenges encountered by site management organizations (SMOs) and investigator site networks. Topping the list of key functionality are streamlined site selection, study start-up project management, and visibility into study conduct across multiple sites.
“Taking complex and data-intensive situations and making them easy to visualize and simple to manage is what the Allegro product line does best,” said Srini Kalluri, Founder, President, CEO and Chief Customer Officer at Forte Research Systems. “Allegro CTMS@Network is a terrific addition to the Allegro product family.”
With an increase in the quantity of trials that are being performed at sites, project managers at SMOs and site networks are not only managing their own workload, but are also trying to monitor and manage the work conducted by busy site staff. This complex environment requires a centralized data repository with sophisticated project management, administrative, and financial tools, in addition to clinical trial management functionality.
Allegro CTMS@Network provides a solution to all these challenges. Through a centralized investigator site database, SMOs and networks are able to get a clear view of their investigator sites in one place and eliminate the need to repeatedly collect the same information. They are able to quickly locate potential sites, find contact information, and communicate with site staff.
Communication regarding activities between the network and sites becomes easy through the use of task lists. By utilizing these lists, project managers can reduce study start-up times, manage activities between sites, and view the status of all sites on a trial at a glance with the task list summary.
For organizations heavily involved with study conduct at the sites, Allegro CTMS@Network provides one centralized calendar that can be used across multiple sites to auto-generate subject visit dates and aid in study management. Detailed trial information such as enrollment, subject status, and drug accountability can be quickly obtained across all participating investigator sites using real-time, customizable reports.
With Allegro CTMS@Network, SMOs and networks are able to leverage powerful built-in customer relationship management tools to track their business development progress in the same system in which they maintain their clinical trial database. Allegro CTMS@Network provides a simple, easy-to-use solution to the unique challenges faced by site and trial management organizations and investigator site networks.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.